|

Daridorexant to Prevent Post-cardiotomy Delirium

RECRUITINGPhase 2Sponsored by University of Rochester
Actively Recruiting
PhasePhase 2
SponsorUniversity of Rochester
Started2025-10-14
Est. completion2027-11-01
Eligibility
Age60 Years+
Healthy vol.Accepted
Locations1 site

Summary

The goal of this follow-on pilot randomized clinical trial is to obtain additional preliminary data to inform a larger, adequately powered phase 2b trial of daridorexant for the prevention of postoperative delirium after heart surgery. Having demonstrated feasibility in a prior study (RSRB #9841), this study aims to estimate the effect of daridorexant on (1) reducing delirium symptom burden and incidence and (2) improving self-reported sleep quality during the postoperative period, and (3) to assess the feasibility of collecting objective sleep data in the postoperative setting. Participants will: complete a baseline visit; take the study drug, either daridorexant or placebo, each of the first three nights after heart surgery; and be evaluated daily for sleep and delirium during the first three postoperative days. Participants will also have the option of wearing a sleep monitor in the hospital each of the first three nights after surgery.

Eligibility

Age: 60 Years+Healthy volunteers accepted
Inclusion Criteria:

* ≥ 60 yrs;
* having surgical aortic valve surgery or coronary artery bypass graft surgery at Strong Memorial Hospital;
* can provide consent;
* able to speak, read,and write English (as the instruments, including semi-structured interviews, used in this protocol have been validated in English);
* family member or close friend for collateral.

Exclusion Criteria:

* Prior cardiotomy
* Infectious endocarditis
* Emergency surgery
* Delirium at baseline (positive 3D-CAM)
* Auditory or visual impairment that prevents study procedures
* Alcohol or substance misuse (CAGE-AID score ≥ 2)
* Psychotic disorder
* Dementia-level deficits (TICS \< 27)
* Use of a prescription sleep aid at least every other night
* Use of a strong CYP3A4 inhibitor (e.g., ceritinib, clarithromycin, cobicistat, idelalisib, itraconazole, ketoconazole, nefazodone, nelfinavir, posaconazole, ritonavir, telithromycin, voriconazole)
* Daridorexant intolerance
* Severe kidney or liver impairment (Child-Pugh ≥7, Cockcroft-Gault \<30 mL/min, or on dialysis)
* Narcolepsy
* Suicidal ideation at baseline
* Any condition that, in the PI's opinion, compromises patient safety or data quality
* Additional exclusions for the NLP exploratory aim: history of traumatic brain injury or head concussions with loss of consciousness, use of corticosteroids, or history of major neurological disease or brain surgery

Conditions4

Alzheimer's DiseaseHeart DiseasePostoperative Cognitive DeclinePostoperative Delirium

Locations1 site

University of Rochester Medical Center
Rochester, New York, 14642
Mark Oldham, MD585-275-3592mark_oldham@urmc.rochester.edu

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.